Scholz now holds oversight of corporate development, external affairs, sales, marketing and public relations at the Beloit, Wisconsin-based diagnostic and therapeutic radiopharmaceuticals company. He was previously responsible for program management, regulatory affairs, engineering and technology, manufacturing operations and supply chain and advanced radioisotope and therapeutic technologies. He will report to CEO Stephen Merrick.
“I want to congratulate Frank Scholz on this well-deserved promotion to President and Chief Operating Officer of NorthStar,” Merrick said in a news release. “Frank’s exceptional success at NorthStar over the last 12 months testifies to his ability to take on additional responsibilities. As a key member of our executive team, Frank will be instrumental in driving NorthStar’s sales of existing and new products. He will be instrumental in expanding NorthStar’s environmentally preferred Mo-99 production capacity and efficiency, developing our next generation of technetium-99m (Tc-99m) generators and advancing a game-changing portfolio of new products, including therapeutic radioisotopes copper-67, actinium-225 and the SPECT imaging agent, FibroScint.”
Scholz previously joined the company in June 2021 as senior VP and chief operating officer. He has more than 20 years of experience in operational experience in the pharmaceutical and life sciences industries. Prior to joining the company, Scholz was the managing director at AlixPartners where he was responsible for leading teams focused on improving the performance of pharmaceutical medical device and provider industries clients. He has held numerous leadership roles at Mallinckrodt and McKinsey.
“The opportunity that lies ahead for NorthStar is extraordinary, and I am very excited to assume this new role at an important juncture in the Company’s development,” Scholz said. “In collaboration with our highly motivated team, we look forward to advancing and implementing high impact programs to support patient health by delivering innovative solutions for radiopharmaceutical development and production.”
